| Predicted Trait | |
| Reported Trait | Atrial fibrillation |
| Mapped Trait(s) | atrial fibrillation (EFO_0000275) |
| Score Construction | |
| PGS Name | PRS_AF |
| Development Method | |
| Name | LDpred |
| Parameters | ρ = 0.03; LD radius = 4000; LD reference panel = 2,690 Finnish individuals [autosomal variants only] |
| Variants | |
| Original Genome Build | hg19 |
| Number of Variants | 6,183,494 |
| Effect Weight Type | NR |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000100 |
| Citation (link to publication) | Mars N et al. Nat Med (2020) |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST006414 Europe PMC: 30061737 |
1,030,836 individuals | European | 6 cohorts
|
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| — | 21,813 individuals, 47.3 % Male samples |
European (Finnish) |
FINRISK | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | Mean (Age At Baseline) = 48.0 years | — | — | Used to select optimal threshold of ρ for all subsequent analyses. FINRISK surveys from 1992, 1997, 2002 and 2007 |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000898 | PSS000439| European Ancestry| 10,561 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident atrial fibrillation | — | C-index: 0.734 | — | CHARGE-AF calculator (age, height, weight, SBP, DBP, smoking status, blood-pressure-lowering medication, diabetes, heart failure and history of myocardial infarction), FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 5-year risk |
| PPM000893 | PSS000439| European Ancestry| 10,561 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident atrial fibrillation | HR: 1.62 [1.54, 1.7] | C-index: 0.751 | — | age, sex, FINRISK cohort, genotyping array/batch, 10 ancestry PCs | 5-year risk |
| PPM000888 | PSS000442| European Ancestry| 135,300 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Atrial fibrillation (incident and prevalent cases) | HR: 1.62 [1.59, 1.65] | — | — | genotyping array/batch, 10 ancestry PCs, stratified by sex | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000439 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
47.3 % Male samples |
Mean (Age At Baseline) = 48.0 years | European (Finnish) |
— | FINRISK | FINRISK surveys from 1992, 1997, 2002 and 2007 |
| PSS000442 | National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9. | — | [ ,
43.7 % Male samples |
Mean (Age At Baseline) = 59.2 years Sd = 16.6 years |
European (Finnish) |
— | FinnGen | — |